查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750874

Remicade市场规模、份额、趋势分析报告：按类型、适应症、分销管道、地区、细分市场预测，2025-2030 年

Remicade Market Size, Share & Trends Analysis Report By Type (Branded, Biosimilar), By Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

Remicade市场成长与趋势

根据Grand View Research的最新报告，预计到2030年全球Remicade市场规模将达到26.2亿美元，2025年至2030年期间的复合年增长率为-2.28%。

儘管品牌主导地位正在逐渐下降，Remicade克隆氏症和类风湿性关节炎等自体免疫疾病全球负担的推动， Remicade（Infliximab）市场仍持续呈现需求。 Remicade 仍然是治疗这些疾病的广泛使用的生物製药。然而，由于生物相似药的进入和接受度不断提高，以及监管政策和医疗保健成本效益策略的不断演变，市场正在发生重大变化。

市场占有率的下降与英夫利西Infliximab生物相似药的广泛应用密切相关。关键地区的专利到期导致生物相似药的供应增加，尤其是在公共医疗体系力求控製成本的国家。这种转变鼓励了更广泛的患者获得治疗，同时也加剧了价格竞争，并挑战了原厂药的地位。儘管如此， Remicade丰富的临床经验和医生对其的熟悉程度支持了其应用，尤其是在复杂病例中。

市场成长机会依然存在，尤其是在生物製药应用仍在不断扩大的地区。在亚洲、拉丁美洲以及中东和非洲的一些市场，医疗基础设施的改善以及人们对发炎性疾病的认知不断提高，推动了对原厂生物製药和生物相似药的需求成长。此外，正在进行的临床研究以及包括皮下给药在内的Infliximab新剂型的研发，也正在推动治疗格局的不断演变。

包括杨森、赛尔群和辉瑞在内的参与Remicade研发的製药公司正在透过诸如区域授权合约、核准后生产合作以及对真实世界证据的投资等策略来应对这一转变。生物相似药开发商也正在利用差异化策略，例如高浓度配方和共同销售协议，来加强其市场渗透率。

Remicade市场报告重点

  • 根据类型，品牌药物将在 2024 年以 52.8% 的销售份额引领市场。这种主导地位归功于医生的强大信任、成熟的临床数据、某些市场对生物相似药的缓慢采用以及患者对品牌的信任。
  • 根据适应症，类风湿性关节炎领域在 2024 年占据市场最大收入份额，达到 20.8%。
  • 根据销售管道，医院药房部门在 2024 年占据了最大的市场收入份额。这是因为直接获得专科护理、强有力的医生推荐以及复杂的自体免疫疾病患者数量众多，使得医院药房成为Remicade（Infliximab）的首选销售管道。
  • 2024年3月，Celltrion宣布计画将原厂药Zymfentra引进美国市场。 Zymfentra是一种用于治疗自体免疫疾病的药物，其上市标誌着Celltrion在生物相似药领域拓展产品组合策略中迈出的重要一步。此举体现了该公司更广泛的策略，即实现产品组合多元化，并利用其在生物製药开发方面的专业知识拓展新的治疗领域。

目录

第一章调查方法与范围

第二章执行摘要

第三章Remicade市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章Remicade市场：按类型进行的业务分析

  • 2024 年及 2030 年各类型市场占有率
  • 类型细分细分仪表板
  • 按类型分類的市场规模、预测和趋势分析（2018-2030 年）
  • 品牌
  • 生物相似药

第五章Remicade市场：按适应症进行的业务分析

  • 2024 年及 2030 年各适应症市场占有率
  • 指示细分仪表板
  • 市场规模、预测与趋势分析（2018-2030 年）
  • 类风湿性关节炎
  • 干癣性关节炎
  • 克隆氏症
  • 溃疡性大肠炎
  • 僵直性脊椎炎
  • 其他的

第六章Remicade市场：按分销管道进行的业务分析

  • 2024 年和 2030 年按分销管道分類的市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
  • 零售药局
  • 网路药局

第七章Remicade市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018年至2030年市场规模与预测趋势分析：
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/列表
    • Janssen Pharmaceuticals（Johnson &Johnson）;
    • Celltrion
    • Pfizer Inc.
    • Boehringer Ingelheim Pharmaceuticals Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • Pfizer Inc.
    • Samsung Bioepis
Product Code: GVR-4-68040-584-4

Remicade Market Growth & Trends:

The global remicade market size is anticipated to reach USD 2.62 billion by 2030 and is projected to decline at a CAGR of -2.28% from 2025 to 2030, according to a new report by Grand View Research, Inc. Despite a gradual decline in brand dominance, the Remicade (infliximab) market continues to show sustained demand, driven by the global burden of autoimmune diseases such as Crohn's disease and rheumatoid arthritis. Remicade has remained a widely prescribed biologic for these conditions. However, the market is undergoing significant change due to the increasing entry and acceptance of biosimilars, supported by evolving regulatory policies and healthcare cost-effective strategies.

The decline in market share is closely tied to the broader availability of biosimilar infliximab options. With patents expiring in key regions, biosimilars have become more accessible, particularly in countries with public healthcare systems seeking cost savings. This shift is encouraging broader patient access to treatment while intensifying price competition, challenging the position of the original product. Still, Remicade's extensive clinical history and physician familiarity support its use, especially in complex cases.

Opportunities for market growth remain, especially in regions where biologic use is still expanding. In markets across Asia, Latin America, and parts of the Middle East and Africa, improvements in healthcare infrastructure and rising awareness of inflammatory diseases are driving increased demand for both originator biologics and biosimilars. Moreover, ongoing clinical research and new infliximab formulations, including subcutaneous delivery, contribute to the evolving therapeutic landscape.

Pharmaceutical companies involved in the Remicade industry, including Janssen, Celltrion, and Pfizer, are responding to these shifts with strategies such as regional licensing deals, post-approval manufacturing partnerships, and investment in real-world evidence. Biosimilar developers also leverage differentiation tactics, including high-concentration formulations and co-marketing agreements, to strengthen market entry.

Remicade Market Report Highlights:

  • Based on type, the branded segment led the market with the largest revenue share of 52.8% in 2024. This dominance is attributable to strong physician trust, established clinical data, slower biosimilar adoption in certain markets, and patient trust in the brand.
  • Based on indication, the rheumatoid arthritis segment led the market with the largest revenue share of 20.8% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
  • Based on distribution channel, the hospital pharmacies segment accounted for the largest market revenue share in 2024, due to their direct access to specialized treatments, strong physician recommendations, and higher patient volumes for complex autoimmune conditions, making them the preferred distribution channel for Remicade (infliximab).
  • In March 2024, Celltrion announced plans to introduce its original drug, Zymfentra, to the U.S. market. The launch of Zymfentra, a treatment for autoimmune diseases, marks a significant step in Celltrion's strategy to expand its portfolio beyond biosimilars. This move reflects the company's broader strategy to diversify its offerings and leverage its expertise in biologic drug development for new therapeutic areas.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Remicade Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Remicade Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded Market, 2018 - 2030 (USD Million)
  • 4.5. Biosimilar
    • 4.5.1. Biosimilar Market, 2018 - 2030 (USD Million)

Chapter 5. Remicade Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Rheumatoid Arthritis
    • 5.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
  • 5.5. Psoriatic Arthritis
    • 5.5.1. Psoriatic Arthritis Market, 2018 - 2030 (USD Million)
  • 5.6. Crohn's Disease
    • 5.6.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
  • 5.7. Ulcerative Colitis
    • 5.7.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
  • 5.8. Ankylosing Spondylitis
    • 5.8.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Remicade Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Remicade Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Remicade Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Janssen Pharmaceuticals (Johnson & Johnson);
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Celltrion
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Pfizer Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Boehringer Ingelheim Pharmaceuticals Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Novartis AG
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Teva Pharmaceutical Industries Ltd
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Pfizer Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Samsung Bioepis
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Type Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Remicade market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 5. Global Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 6. Global Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America Remicade market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 9. North America Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 10. North America Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11. U.S. Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 12. U.S. Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 13. U.S. Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14. Canada Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 15. Canada Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 16. Canada Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Mexico Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 18. Mexico Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 19. Mexico Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Europe Remicade market, by country, 2018 - 2030 (USD Million)
  • Table 21. Europe Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 22. Europe Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 23. Europe Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. UK Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 25. UK Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 26. UK Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27. Germany Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 28. Germany Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 29. Germany Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. France Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 31. France Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 32. France Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Italy Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 34. Italy Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 35. Italy Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36. Spain Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 37. Spain Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 38. Spain Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39. Norway Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 40. Norway Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 41. Norway Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Denmark Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 43. Denmark Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 44. Denmark Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Sweden Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 46. Sweden Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 47. Sweden Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific Remicade market, by country, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52. Japan Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 53. Japan Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 54. Japan Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55. China Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 56. China Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 57. China Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. India Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 59. India Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 60. India Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Australia Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 62. Australia Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 63. Australia Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64. South Korea Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 65. South Korea Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 66. South Korea Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Thailand Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 68. Thailand Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 69. Thailand Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. Latin America Remicade market, by country, 2018 - 2030 (USD Million)
  • Table 71. Latin America Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 72. Latin America Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 73. Latin America Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. Brazil Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 75. Brazil Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 76. Brazil Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77. Argentina Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 78. Argentina Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 79. Argentina Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa Remicade market, by country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84. South Africa Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 85. South Africa Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 86. South Africa Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. UAE Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 91. UAE Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 92. UAE Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93. Kuwait Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 94. Kuwait Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 95. Kuwait Remicade market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Remicade market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and indication outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Remicade market dynamics
  • Fig. 12 Remicade market: Porter's five forces analysis
  • Fig. 13 Remicade market: PESTLE analysis
  • Fig. 14 Type market, 2018 - 2030 (USD Million)
  • Fig. 15 Branded market, 2018 - 2030 (USD Million)
  • Fig. 16 Biosimilar market, 2018 - 2030 (USD Million)
  • Fig. 17 Indication market, 2018 - 2030 (USD Million)
  • Fig. 18 Rheumatoid Arthritis market, 2018 - 2030 (USD Million)
  • Fig. 19 Psoriatic Arthritis market, 2018 - 2030 (USD Million)
  • Fig. 20 Crohn's Diseases market, 2018 - 2030 (USD Million)
  • Fig. 21 Ulcerative Colitis market, 2018 - 2030 (USD Million)
  • Fig. 22 Ankylosing Spondylitis market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 25 Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 26 Retail Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 27 Online Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 28 Remicade market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America Remicade market, 2018 - 2030 (USD Million)
  • Fig. 32 US country dynamics
  • Fig. 33 US Remicade market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada Remicade market, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico Remicade market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Remicade market, 2018 - 2030 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK Remicade market, 2018 - 2030 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany Remicade market, 2018 - 2030 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France Remicade market, 2018 - 2030 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy Remicade market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain Remicade market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway Remicade market, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden Remicade market, 2018 - 2030 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark Remicade market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific Remicade market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan Remicade market, 2018 - 2030 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China Remicade market, 2018 - 2030 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India Remicade market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia Remicade market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea Remicade market, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand Remicade market, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America Remicade market, 2018 - 2030 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil Remicade market, 2018 - 2030 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina Remicade market, 2018 - 2030 (USD Million)
  • Fig. 73 MEA Remicade market, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa Remicade market, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia Remicade market, 2018 - 2030 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE Remicade market, 2018 - 2030 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait Remicade market, 2018 - 2030 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework